All In Biotech

Drug Trial Radar · NCT05944848

A Study of CL-197 Capsules in Healthy Participants

A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of CL-197 Capsules Administered in Single Dose in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

44

Actual

Start

Nov 16, 2022

Primary completion

Jan 20, 2024

Study completion Jan 20, 2024

Sponsor

Sponsor type
Industry
First posted
Jul 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetic characteristics of CL-197 capsules in health conditions.

Conditions

  • HIV-1

Interventions

  • 1 mg CL-197 capsulesDrug

    Single oral dose of 1 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast

  • 10 mg CL-197 capsules or CL-197 placeboDrug

    Single oral dose of 10 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast

  • 30 mg CL-197 capsules or CL-197 placeboDrug

    Single oral dose of 30 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast

  • 60 mg CL-197 capsules or CL-197 placeboDrug

    Single oral dose of 60 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast

  • 100 mg CL-197 capsules or CL-197 placeboDrug

    Single oral dose of 100 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Safety and Tolerability of CL-197 Capsules :Incidence of Treatment-Emergent Adverse Events as Assessed by The NCI CTCAE V5.0 Grading CriteriaTime frame: Up to 29 days post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Fifth Medical Center of Chinese PLA General Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.